Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis
Reich, Kristian (University Medical Center Hamburg-Eppendorf)
Conrad, Curdin (University Hospital Lausanne CHUV)
Kristensen, Lars Erik (Lund University)
Smith, Saxon (The University of Sydney)
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau)
Rich, Phoebe (Oregon Dermatology and Research Center)
Sapin, Christophe (Eli Lilly and Company)
Holzkaemper, Thorsten (Eli Lilly and Company)
Koppelhus, Uffe (Eli Lilly and Company)
Schuster, Christopher (Medical University of Vienna)
Universitat Autònoma de Barcelona

Data:	2022
Resum:	Nail psoriasis (NP) is common and of high importance in patients with psoriasis. Complete resolution of NP at week 24‒26 is an unambiguous nail outcome accessible for indirect treatment comparison of biologics. To evaluate the comparative efficacy of approved biologics in achieving complete resolution of NP at week 24‒26. A network meta-analysis (NMA) was conducted to indirectly compare the efficacy of six biologics in achieving complete resolution of NP at week 24‒26 in patients with moderate-to-severe psoriasis and concomitant NP. Complete resolution of NP was defined as a score of zero on the Nail Psoriasis Severity Index (NAPSI), modified NAPSI (mNAPSI) or Physician's Global Assessment of Fingernails (PGA-F). The probability of achieving complete resolution of NP was highest for ixekizumab (46. 5%; 95% credibility interval [CrI] 35. 1‒58. 0; Surface Under the Cumulative RAnking curve [SUCRA] 97%), followed by brodalumab (37. 0%; 17. 0‒61. 0; 79%), adalimumab (28. 3%; 24. 4‒32. 4; 62%), guselkumab (27. 7%; 21. 1‒35. 1; 58%), ustekinumab (20. 8%; 10. 2‒35. 2; 37%), and infliximab (0. 8%; 0. 0‒8. 9; 17%). In patients with moderate-to-severe psoriasis and concomitant NP, ixekizumab has the greatest likelihood among approved biologics of achieving complete resolution of NP at week 24‒26. Findings should be interpreted carefully because of inherent study limitations.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Biologics ; Complete clearance/resolution of nail psoriasis ; Ixekizumab ; Nail Psoriasis Severity Index (NAPSI) ; Nail psoriasis ; Network meta-analysis ; Physician's Global Assessment of Fingernails (PGA-F)
Publicat a:	Journal of Dermatological Treatment, Vol. 33 Núm. 3 (2022) , p. 1652-1660, ISSN 1471-1753

DOI: 10.1080/09546634.2021.1892024
PMID: 33641593

10 p, 1.8 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats